Efficacy and Safety of a 4-Week Course of Repeated Subcutaneous Ketamine Injections for Treatment-Resistant Depression: KADS Study - Randomised, Double-blind, Active-controlled Trial

Abstract:

This article presents the findings of a randomised, double-blind, active-controlled trial known as the Ketamine for Treatment-Resistant Depression Study (KADS). The study aimed to evaluate the efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections in individuals with treatment-resistant depression.

Introduction: 

Treatment-resistant depression poses significant challenges in clinical psychiatry. Existing antidepressant therapies often yield limited results, necessitating the exploration of alternative treatment options. Ketamine, a glutamatergic N-methyl-D-aspartate receptor antagonist, has shown promise as a potential therapeutic intervention for treatment-resistant depression. This study aimed to assess the efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections in this patient population.

Methods: 

The KADS study employed a randomised, double-blind, active-controlled design to investigate the effects of repeated subcutaneous ketamine injections. The participants, diagnosed with treatment-resistant depression, were randomly assigned to receive either subcutaneous ketamine injections or an active control treatment. The primary outcome measures were the change in Montgomery-Åsberg Depression Rating Scale (MADRS) scores from baseline to week 4. Secondary outcome measures included response rates, remission rates, and safety assessments.

Results:

A total of [number] participants were enrolled in the study, with [number] assigned to the subcutaneous ketamine injection group and [number] to the active control group. The study found that the group receiving subcutaneous ketamine injections exhibited a significant reduction in MADRS scores compared to the active control group (p-value < 0.05). Furthermore, a higher proportion of participants in the ketamine group achieved response and remission criteria compared to the control group. The safety assessments indicated an acceptable tolerability profile, with no significant adverse events reported.

Conclusion:

The findings of the KADS study suggest that a 4-week course of repeated subcutaneous ketamine injections holds promise as an effective and safe treatment option for individuals with treatment-resistant depression. The observed reduction in MADRS scores, along with the higher response and remission rates, supports the use of subcutaneous ketamine injections in this patient population. Further research is warranted to explore the long-term effects and potential mechanisms underlying the therapeutic benefits of ketamine in treatment-resistant depression.